with the growing prevalence of dementia, scientists are trying to study the viable treatment. Some people focus on the culprit of neuronal cell death, trying to reduce the formation of beta-amyloid protein; others are committed to promoting nerve cell regeneration, hoping to make up for nerve cell damage vacancies, probably a Kind of "missing and then make it back" concept.
In the adult mammalian brain, there are two regions that will continue to produce new nerve cells, one of which is in the hippocampus. These nerve cells with self-proliferative ability, known as "neural progenitor cells (also known as neural progenitor cells)", by its new cells will be added to the original neural circuit to help learn new skills and new The formation of memory.
However, regardless of in humans or mice can be observed, Alzheimer's disease will make nerve progenitor cell proliferation capacity disorders. There is now growing evidence that promoting progenitor cell proliferation can reduce the cognitive degradation caused by Alzheimer's disease and is expected to be a viable strategy for the treatment of Alzheimer's disease.
This year (2017) in January, by the Shanghai Tongji University, the Chinese Academy of Sciences Shanghai Academy of Life Sciences and other co-published in the "Stem Cell Reports" ("stem cell report") research results show that through animal experiments and cell experiments show that Ganoderma also have this The potential of:
Whether it is Ganoderma lucidum water extract, or from the Ganoderma lucidum fruiting body derived from pure polysaccharides (protein, molecular weight of 15 kD) can reduce the cognitive impairment caused by Alzheimer's disease, reduce brain profile beta amyloid Deposition, and promote the hippocampus nerve precursor cells new. While the latter mechanism of action is likely to be associated with a neural precursor cell called a FGFR1 receptor, which is active because of the regulation of Ganoderma lucidum polysaccharide.